Latest Interviews
Showing 1–5 of 5 transcripts.
Clear all filters- Milken Institute58 min
Poised to Break the Bank: Paying for Chronic Disease
Allison, Anand, Tom, Nancy, Paul Davis, Eric, Michael Golinkoff, John Rother, Megan Golden, Jess Leifer, Stephanie Cousins
A multi-sector consensus addresses the $2.4 trillion annual burden of chronic U.S. diseases by implementing interventions like Geisinger's Food Pharmacy, which reduces healthcare costs by aligning patient acuity with intensive lifestyle support. While capitated payment models and digital innovations such as Omada Health improve scalability and outcomes, structural barriers including payer misalignment and low screening rates for prediabetes necessitate policy shifts toward sugar taxes and multi-payer funding. Concurrently, the medical landscape is pivoting from opioid reliance to holistic pain management and gene therapies, with academic institutions like Kaiser Permanente adapting curricula to prioritize prevention and address the mental health needs of 74% of employees.
- Milken Institute1h 1m
Credit Markets: What's Next?
Mike Milken, Rich Byrne, David Warren, Tom, Steve, Michael
Regulatory constraints have forced banks to retreat from middle-market lending, creating a liquidity vacuum now filled by alternative capital providers such as Business Development Companies and institutional investors actively engaging in bespoke direct origination. This structural shift compels pension funds and credit managers to abandon passive index strategies in favor of deep fundamental analysis and flexible capital deployment across complex assets like legacy CMBS and emerging market debt to achieve realistic returns. By acting as both lenders and equity partners in distressed or restructuring scenarios, these active managers are capitalizing on a sustained "golden era" of institutional credit investment driven by regulatory disintermediation.
- Milken Institute1h 1m
The Catalyst for Change: What's Working in Philanthropy -- and What's Not?
Rich, Paul, Rochelle, Tom, Adam, Tzitzi, Hulunrosho, Michael Greenstone
This session outlines a strategic shift in philanthropy from passive funding to impact-driven capital that prioritizes fiscal responsibility and measurable results across global challenges. Experts detail specific initiatives ranging from biometric verification for widows and orphans to government-backed pilot programs that transition communities from dependency to entrepreneurship through rigorous evaluation models. By highlighting successful mergers, pharmaceutical commercialization, and the critical need for professional talent development, the dialogue emphasizes a future where sustainable economic models replace temporary aid to solve systemic issues in education, healthcare, and disaster response.
- Milken Institute57 min
The 2014 Atlanta Summit - - The Business Case for Public Health
Mike Milken, Mahmoud, Rajiv, Steve Byrd, Bob, Judy, Leisha Hancock, Tom
This event synthesizes perspectives from the CDC, PepsiCo, Fidelity, Safeway, and the pharmaceutical sector to highlight a systemic shift from isolated interventions to cross-sector collaboration for managing chronic disease and innovation. Participants detailed how major corporations are reducing health risks through data-driven strategies, such as PepsiCo's portfolio reformulation and Safeway's biometric incentives, while biotech investors address the funding gap for high-risk scientific breakthroughs. Ultimately, the discussion emphasizes that saving lives requires a unified ecosystem where government agencies, private industry, and academic centers align resources to tackle preventable mortality and unsustainable healthcare costs.
- Milken Institute54 min
The 2014 Atlanta Summit - - Lunch Program
Judith, Trevor, Mike, Carmen, Frida, Tom
This event examines the century-long strategic evolution of major philanthropies like the Rockefeller Foundation, detailing their pivot from medical cures to integrated public health systems and the resulting cross-disciplinary fields. It highlights modern innovations such as geospatial data integration for polio eradication and the rise of non-traditional partnerships between governments, pharmaceutical giants like Pfizer, and patient advocacy groups to address both infectious and non-communicable diseases. The discussion further underscores global health security challenges, including antimicrobial resistance and pandemic preparedness, while showcasing how mobile technology and crowdsourcing enable developing nations to leapfrog infrastructure barriers.